The call highlighted Centene's 2025 earnings results, noting a Q4 loss per share of $1.19 and full-year adjusted EPS of $2.80. Challenges were met with disciplined execution, improving Medicaid profitability and setting a solid foundation for 2026. The company expects over 20% adjusted EPS growth in 2026, driven by Medicaid margin stability, marketplace recovery, and progress toward Medicare Advantage breakeven. Initiatives include network optimization, clinical program implementation, rate advocacy, and enhanced fraud detection, with a focus on quality outcomes and taxpayer stewardship.

Marketplace medical costs trended slightly better than expected, with updated 2025 data showing favorable developments. Two out-of-period items, including CMS reconciliation and NSA disputes, led to additional accruals. Advocacy for NSA reform continues amidst increased weaponization for profit, prompting a proactive stance. A lawsuit against a New York provider for alleged fraud was filed. Enhanced operational support during a dynamic open enrollment period highlights the team's strong execution.

The dialogue outlines projections for 2026, emphasizing paid membership as a key metric, noting a shift towards bronze plans, and anticipating a positive risk adjustment position. It highlights Medicare Advantage's strong performance, strategic membership adjustments, and plans for improved profitability and service, focusing on dual eligible members and stars improvement.

The dialogue emphasizes the company's strategic focus on integrating AI and data technologies to improve operational efficiency, member engagement, and fraud detection. It outlines plans for 2026, including margin expansion and maintaining a member-centric approach, while navigating policy-related challenges. The team's commitment to leveraging advanced analytics and automation is highlighted as key to achieving industry-leading outcomes.

The company reported 2025 Q4 and full year results with $174.6 billion in revenue and $2.08 adjusted diluted EPS. A $2.24 GAAP loss per share was noted due to a Magellan business divestiture. Underlying adjusted earnings met forecasts, setting a positive tone for future guidance.

The dialogue outlines the financial performance and expectations for 2026, focusing on Medicaid, commercial, and Medicare segments. It highlights progress in Medicaid HBR improvement, commercial segment trends, and Medicare PDP and Advantage business growth, while addressing challenges like membership attrition and cost increases.

Centene anticipates a 2026 HBR recovery, driven by marketplace and Medicare Advantage improvements, with a flat Medicaid segment. Expectations include a higher PDP HBR due to premium and pharmacy expense increases, offset by reduced interest expenses and continued debt paydown. The forecast projects greater than $3 EPS, reflecting marketplace margin turnaround and lower interest costs, with no share buybacks in guidance.

A detailed discussion on Medicaid rate justification for 2026 highlights constructive conversations with state partners, favorable rate trends from 2025, and efforts to manage healthcare costs. The 4.5 percent rate assumption for 2026 is deemed prudent, considering the acuity dynamics and increased trend encapsulated in the data. The speaker also mentions the work done in 2025 to address trend, which contributes to the assumption of a flat HR year over year.

Discussion on Medicaid's projected 4.5% trend rate in 2026, contrasting with 2025's mid-sixes, highlights actions taken to bend the trend. States' justification for lower 4.5% rates involves recent trend data, program changes, and proof points from 2025's second half, aiming for a flat HBR year-over-year, with an emphasis on achieving more than just rate adjustments.

Discusses confidence in margin improvement for exchanges in 2026, attributing it to strong execution, visibility into membership trends, and historical data analysis, despite changes in metal tier distribution.

The dialogue discusses the projected decline in Medicaid membership months, attributing a significant portion to ongoing attrition patterns observed in 2025. It highlights the acuity impact of continued disenrollment rates and mentions specific program changes, such as the Florida CMS program rolling off, alongside a probability-weighted estimate of member attrition. The conversation reassures that these factors have been prudently factored into the guidance, with further details on membership attrition and impacts from OB 3 provisions being provided.

The discussion focuses on efforts to reduce the lag in the actuarial soundness look-back process, emphasizing the importance of incorporating more recent data to better align rates with current trends, particularly in response to disruptions like redeterminations and work requirements. States are encouraged to proactively engage and share updated data, exemplified by successful rate corrections in Florida. This collaborative approach aims to preempt future rate adjustments and refine programs to manage budget pressures effectively, ensuring timely and accurate cost of care assessments.

Discussion covers segment margins implied in 2026 guidance, with emphasis on margin improvement opportunities across businesses. Commercial segment aims for around 4% pre-tax, Medicare PDP targets around Ed, and Medicare Advantage nears break-even without Pdr, indicating slight loss on full allocation basis.

A discussion on varying Medicaid margin forecasts among national peers and the effect of a renegotiated PBM contract, with a focus on geographic footprint and contract benefits.

The dialogue emphasizes the importance of strategic execution and aggressive actions taken in the latter half of the year, which have set a strong foundation for continued growth in 2026. It highlights key levers such as network optimization, clinical management, and fraud prevention, which have positively impacted the P&L and are poised to deliver further benefits. The speaker reiterates the need for prudent rate assumptions, aiming for a net trend of 4.5% in 2026, reflecting the efforts made to manage healthcare costs. Additionally, the discussion touches on the long-standing partnership with a PBM, emphasizing the value of a tailored and flexible contract that enhances collaboration and drives affordability in healthcare services for low-income and medically complex members.

Discusses the impact of IRA on non-Low Income (LIS) populations in Part D, highlighting successful revenue growth driven by yield increases and direct subsidy, emphasizing the company's underwriting acumen, cost structure, and commitment to providing affordable drug programs for seniors, while navigating challenges post IRA and positioning for continued profitability.

The dialogue explores Medicaid trends, highlighting risk shift impacts, benefit design changes, and core trend drivers like behavioral health and high-cost drugs. It discusses competitive pressures affecting smaller plans and the importance of sufficient funding to maintain quality services. Inpatient trends and TANF populations are noted as areas of interest for trend mitigation strategies.

Discussion focused on the incremental pressure within Medicare Advantage, beyond the PDP reset, attributed to subsidy changes and their impact on premium revenue and medical costs, affecting breakeven targets.

Discussion focused on the impact of trading down to bronze health plans, with early data suggesting no alarming changes in utilization patterns or cost trends, aligning with pre-established expectations.